Puma Biotechnology (NASDAQ:PBYI)‘s stock had its “buy” rating restated by equities researchers at Citigroup Inc. in a research report issued on Tuesday. They currently have a $99.00 price target on the stock, down from their previous price target of $123.00. Citigroup Inc.’s target price points to a potential upside of 59.27% from the company’s current price.
Shares of Puma Biotechnology (NASDAQ:PBYI) opened at 62.16 on Tuesday. Puma Biotechnology has a 52 week low of $33.70 and a 52 week high of $143.65. The stock has a 50-day moving average of $64.14 and a 200-day moving average of $94.93. The company’s market cap is $1.872 billion.
Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Monday, May 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.19. On average, analysts predict that Puma Biotechnology will post $-2.56 earnings per share for the current fiscal year.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with Analyst Ratings Network's FREE daily email newsletter.